



RAS Signaling Pathway in Cancer Therapy

Guest Editor:

Dr. Matthias Drosten

Centro de Investigación del
Cáncer, Instituto de Biología
Molecular y Celular del Cáncer
(CSIC-USAL), Salamanca, Spain

Deadline for manuscript
submissions:

closed (5 January 2025)

Message from the Guest Editor

Dear Colleagues,

Mutations in one of the *RAS* genes are found in a quarter of all human cancers. Given that RAS signaling plays a critical role in several cellular activities such as cell proliferation, a deeper understanding of RAS signaling in cancer, but also in development or homeostasis, is urgently required to further improve the therapeutic options for patients with tumors harboring *RAS* mutations.

The scope of this Special Issue is to further advance our understanding of the unique requirements for RAS signaling in distinct contexts such as tumor initiation, growth, or maintenance. Genetic studies in particular, although not exclusively, have the potential to uncover novel vulnerabilities that may ultimately expand the therapeutic options for patients with acquired or even intrinsic resistance. More importantly, genetic studies can also provide knowledge regarding essential requirements for RAS signaling in more universal contexts, with the final goal being to keep the therapy-related toxicities as low as possible.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)